Strong performance for the sector is sending many biotech stocks to 52-week highs. Plus, the strong market is encouraging dozens of new companies to go public in biotech IPOs.
Promising young biotech stocks are among the biggest winners. This is especially true for companies developing vaccines for the virus.
Just check out these recent biotech IPOs:
- 346% in Twist Bioscience
- 391% in BioNTech
- 394% in Kodiak Sciences
- 412% in Principia Biopharma
- 440% in Karuna Therapeutics
54 stocks in the healthcare and biotech sector have already gone public.
“During Covid-19 pandemic, biotech IPOs already surpass record,” reports The Wall Street Journal.
U.S. biotech IPOs have already raised $9.4 billion.
That’s far ahead of the $6.5 billion raised during 2018 – which was the biggest year for biotech IPOs.
Strong gains for the sector are making it easy for biotech stocks to attract new investors.
The iShares Nasdaq Biotech ETF (NASDAQ: IBB) is posting year-to-date gains of 12%. That may not seem significant. However, the biotech index is beating the S&P 500 by three times.
Most investors are overwhelmed when it comes to biotechs.
That means they’ll typically simply invest in an ETF such as IBB. Or they’ll buy shares of well-known biotech stocks such as Gilead Sciences (NASDAQ: GILD) or Amgen (NASDAQ: AMGN).
Those types of biotechs are fine – if you’re satisfied with gains of 10% – 15% per year.
Yet folks looking for bigger profits need to look at the emerging biotechs . . . because it’s the smaller companies with major drug breakthroughs that really pay off for investors.
That’s why I’m so excited about this . . .
One undiscovered biotech is quietly preparing to go public in the next couple months.
The company is already partnered with Pfizer (NYSE: PFE) – a $50 billion pharma giant. And it’s working on promising new drug treatments for Parkinson’s disease, schizophrenia and epilepsy.
Top Wall Street firms are already lining up and buying Pre-IPO shares. And these firms include T. Rowe Price, Fidelity Investments, and a leading private equity firm called Bain & Co.
Why are they scooping up Pre-IPO shares?
Because the average biotech stock jumps 34% on its first trading day.
Here’s the thing . . .
YOU can also grab Pre-IPO shares today – right before the stock goes public.